Although the association between JAK2 V617F mutation and vascular abnormalities, including aneurysm formation, has been increasingly recognized, routine aneurysm screening is not currently recommended for MPN patients with JAK2 mutations, as evidence remains limited and no consensus guidelines exist. Here, JAK2 is linked to myeloproliferative neoplasm.